Posted on January 20th, 2012 by
The lawsuit between Prometheus Laboratories and Mayo Clinic, which started in 2004, reached the Supreme Court last December. During oral arguments justices repeatedly asked lawyers for both sides to offer them direction on one key question: When does a claim involving diagnostic and treatment-related chemical observations, among examples of natural phenomena, meet the threshold for patent eligibility? The justices didn’t get the clear answer they sought.
Genetic Engineering & Biotechnology News, 1/10/2012
Tags: Legal / Leadership
You must be logged-in to the site to post a comment.